The company expired its plan on December 31, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.31 USD | +2.34% |
|
+20.18% | +48.86% |
Jul. 02 | Atossa Therapeutics Names Heather Rees CFO | MT |
Jul. 02 | Atossa Therapeutics, Inc. Appoints Heather Rees as Chief Financial Officer | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+48.86% | 165M | |
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |
- Stock Market
- Equities
- ATOS Stock
- News Atossa Therapeutics, Inc.
- Atossa Therapeutics, Inc.'s Equity Buyback announced on June 27, 2023, has expired with 1,320,046 shares, representing 1.04% for $1.44 million.